Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma. - Shitara K; Bang YJ; Wyrwicz LS; Rha SY; Oshima T; Pietrantonio F; Park YK; Lonardi S; Yañez P; Yen CJ; Metges JP; Garrido M; et al. (ESMO open, 2026)